Rhumatologie

No superiority of infliximab (INF) + methotrexate (MTX) over INF alone in the treatment of ankylosing spondylitis (AS): results of a one-year randomized prospective study

Poster – 69ème Congrès ACR – San Diego (Californie- USA) – 15-17/12/2005 Breban M, Ravaud P, Claudepierre P, Baron G, Hudry C, Euller Ziegler L, Pham T, Flipo RM, Chary-Valckenaere I, Marcelli C, Perdriger A, Le Loet X, Wendling D, Fautrel B, Fournie B, Combe B, Gaudin P, Saraux A, Mariette X, Baleydier A, Dougados M.

Vous souhaitez échanger
avec nos équipes

Contactez-nous

D’autres articles qui pourraient
vous intéresser

Impact of disease activity for patients with axial spondyloarthritis
Rhumatologie

Impact of disease activity for patients with axial spondyloarthritis

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis
Rhumatologie

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis

Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France
Rhumatologie

Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France